Video Experimental Relacionado
Updated: Feb 11, 2026
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.8K
Agonistas del receptor GLP-1 en el asma: dirigidos a las encrucijadas metabólico-inflamatorias
Helen O'Brien1,2, Alessandro N Franciosi1,2, Marcus W Butler1,2
1Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin.
Current opinion in pulmonary medicine
|February 10, 2026
Resumen
Los agonistas del receptor del péptido-1 parecido al glucagón son prometedores para el manejo del asma, particularmente en pacientes con obesidad o diabetes. Se necesita más investigación para comprender sus mecanismos y su uso óptimo en el tratamiento del asma.
Área de la Ciencia:
- La Medicina Metabólica es una Medicina Metabólica.
- Pulmonología Pulmonología.
- Farmacología Farmacología.
Sus antecedentes:
- La obesidad agrava el asma, lo que lleva a un mal control de la enfermedad y a una respuesta reducida al tratamiento.
- La pérdida de peso y la modulación metabólica muestran potencial para mejorar los resultados del asma.
- La evidencia emergente sugiere un vínculo entre la resistencia a la insulina y el control del asma, independientemente del peso.
Objetivo del estudio:
- Revisar el papel emergente de los agonistas de los receptores de péptido-1 similares al glucagón (GLP-1RA) en el manejo del asma.
- Explorar el potencial de GLP-1RAs como terapias adicionales para el asma no controlada, especialmente en pacientes con obesidad comórbida o diabetes.
- Para resaltar la intersección de las vías metabólicas e inflamatorias en el tratamiento del asma.
Principales métodos:
- Revisión de recientes estudios traslacionales, mecanicistas y de observación.
- Análisis de meta-análisis que investigan las GLP-1RA en el asma.
- Evaluación de la comprensión actual de los mecanismos GLP-1RA en el asma.
Principales resultados:
- Los GLP-1RA demuestran una señal positiva en la mejora de la atención del asma para individuos obesos y no obesos.
- La modulación de la resistencia a la insulina a través de GLP-1RA puede mejorar el control del asma, independientemente de la pérdida de peso.
- Las GLP-1RAs representan un nuevo enfoque terapéutico en el nexo inflamatorio y metabólico para el asma incontrolada.
Conclusiones:
- Los ARR del GLP-1 son reconocidos por su potencial en el tratamiento de pacientes con asma con obesidad y/o diabetes.
- Los mecanismos precisos de la acción de GLP-1RA en estos grupos de pacientes requieren una mayor aclaración.
- Los ensayos controlados aleatorios son esenciales para determinar los beneficios, los daños y la integración óptima de los ARRs GLP-1 en las pautas de tratamiento del asma.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:25Drug-Receptor Interaction: Agonist
4.1K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.1K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.0K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.0K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
523
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
523
01:29Asthma-I: Introduction
3.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.6K
00:52What is Metabolism?
132.2K
Overview
132.2K